Oppenheimer Survey of Patient Therapy Combinations Show Relypsa (RLYP) Concern Overblown
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Nasdaq hits record high after softer jobs data tempers rate-hike bets
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- Wells Fargo names 13 stocks as overweight tactical ideas
RELYPSA ANNOUNCES FDA APPROVAL OF VELTASSA(TM) (PATIROMER) FOR ORAL SUSPENSION FOR THE TREATMENT OF HYPERKALEMIA
October 21, 2015 8:34 PM EDTFirst new medicine for the treatment of hyperkalemia, or high blood potassium levels, in more than 50 years Approximately 3 million people with chronic kidney disease (CKD) and/or heart failure in the United States have hyperkalemia In clinical trials, Veltassa significantly reduced blood potassium and kept levels in the target range for up to a year in patients with hyperkalemia, allowing for chronic, daily treatment of hyperkalemia Company to hold conference call/webcast Thursday, October 22, 2015 at 8:00AM ET (5:00AM PT)
REDWOOD CITY, Calif., Oct. 21, 2015 (GLOBE NEWSWIRE) --... More
